| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 164.81▼ | 164.98▼ | 165.22▼ | 163.06▲ | 171.48▼ |
| MA10 | 164.84▼ | 165.51▼ | 165.15▼ | 166.18▼ | 174.86▼ |
| MA20 | 164.96▼ | 165.13▼ | 164.35▲ | 172.23▼ | 167.92▼ |
| MA50 | 165.42▼ | 163.92▲ | 165.04▼ | 175.41▼ | 153.36▲ |
| MA100 | 165.36▼ | 165.36▼ | 169.79▼ | 166.07▼ | 151.87▲ |
| MA200 | 164.49▲ | 170.62▼ | 174.55▼ | 155.90▲ | 133.76▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.001▲ | -0.174▼ | 0.166▲ | -1.147▼ | -1.416▼ |
| RSI | 32.029▼ | 47.013▼ | 49.205▼ | 34.612▼ | 50.153▲ |
| STOCH | 29.563 | 16.185▼ | 48.118 | 18.039▼ | 49.750 |
| WILL %R | -100.000▼ | -84.581▼ | -68.571 | -79.178▼ | -80.079▼ |
| CCI | -208.405▼ | -85.764 | -11.004 | -57.159 | -101.780▼ |
|
Thursday, April 18, 2024 10:44 AM
Cerevel Therapeutics Holdings Inc. (NASDAQ:CERE) released topline results from its pivotal Phase 3 TEMPO-3 trial for tavapadon in Parkinson’s disease. The TEMPO-3 trial evaluated the efficacy, safety, ...
|
|
Thursday, April 18, 2024 09:18 AM
AbbVie’s acquisition of neuroscience biotech Cerevel Therapeutics hasn’t closed yet. But the latest results from Cerevel’s Parkinson’s disease late-stage trial just made the deal look even better.
|
|
Thursday, April 18, 2024 08:12 AM
April 18, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from SELECT-GCA, a Phase 3, multicenter, randomized, double-blind, placebo-controlled study, showing ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 18/04/24 | 164.91 | 167.44 | 164.50 | 164.56 | 3,650,460 |
| 17/04/24 | 164.15 | 164.74 | 163.23 | 164.25 | 4,792,382 |
| 16/04/24 | 162.18 | 163.74 | 162.0772 | 162.54 | 4,881,516 |
| 15/04/24 | 164.52 | 164.70 | 161.50 | 161.67 | 5,433,730 |
| 12/04/24 | 164.45 | 164.45 | 160.00 | 162.28 | 7,029,475 |
| 11/04/24 | 169.20 | 169.37 | 167.227 | 167.52 | 3,307,034 |
| 10/04/24 | 168.59 | 169.96 | 167.36 | 169.03 | 3,231,664 |
| 09/04/24 | 169.73 | 170.545 | 167.395 | 170.14 | 5,933,987 |
| 08/04/24 | 169.21 | 171.97 | 168.40 | 169.80 | 4,744,996 |
| 05/04/24 | 168.00 | 171.04 | 167.29 | 170.00 | 7,030,108 |
|
|
||||
|
|
||||
|
|